Cevimeline

BreastfeedingPediatric
  • TRADE NAME: Evoxac (Daiichi Sankyo)
  • INDICATIONS: Sicca syndrome in patients with Sjøgren’s syndrome
  • CLASS: Muscarinic cholinergic agonist
  • HALF-LIFE: 3–4 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: C

NOTE

Contra-indicated in patients with uncontrolled asthma, acute iritis or narrow-angle glaucoma.

Our database has 89 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RESPIRATORY.
OTHER.


Page last updated 07/31/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top